StockDrifts LogoStockDrifts

Highvista Strategies 13F Portfolio

Portfolio Manager
Highvista Strategies LLC
Performance
+22.57% (2026 Q2)
AUM (13F)
$438.60M
# of Holdings
147
Performance Rank
Allocation (Top 20)
43.88%
Latest filing
Q2 2026

Highvista Strategies LLC Holdings Map

Top 50 Highvista Strategies LLC Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
DBC
INVESCO DB COMMDY INDX TRCK
6.43%1.06M$28.2M
+0.00%(+0)
2025-Q2: 1.44M shares2025-Q3: 1.44M shares2025-Q4: 1.06M shares2026-Q1: 1.06M shares2026-Q2: 1.06M shares
$22.91(+30.00%)
2026-06-30
ABVX
ABIVAX SA
3.43%113.0K$15.1M
-0.20%(-223)
2025-Q2: 51.2K shares2025-Q3: 184.5K shares2025-Q4: 72.2K shares2026-Q1: 113.3K shares2026-Q2: 113.0K shares
$68.13(+83.12%)
2026-06-30
RVMD
REVOLUTION MEDICINES INC
2.86%67.0K$12.5M
-3.36%(-2.33K)
2025-Q2: 68.0K shares2025-Q3: 175.4K shares2025-Q4: 120.2K shares2026-Q1: 69.3K shares2026-Q2: 67.0K shares
$39.86(+406.74%)
2026-06-30
DFTX
DEFINIUM THERAPEUTICS INC
2.6%242.9K$11.4M
+30.68%(+57.03K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 185.9K shares2026-Q2: 242.9K shares
$19.93(+120.26%)
2026-06-30
IMVT
IMMUNOVANT INC
2.44%277.9K$10.7M
+23.42%(+52.73K)
2025-Q2: 182.8K shares2025-Q3: 253.1K shares2025-Q4: 221.9K shares2026-Q1: 225.1K shares2026-Q2: 277.9K shares
$20.35(+105.50%)
2026-06-30
PRAX
PRAXIS PRECISION MEDICINES I
2.31%30.2K$10.1M
+14.77%(+3.89K)
2025-Q2: 67.3K shares2025-Q3: 95.0K shares2025-Q4: 25.8K shares2026-Q1: 26.3K shares2026-Q2: 30.2K shares
$85.80(+344.34%)
2026-06-30
RLAY
RELAY THERAPEUTICS INC
2.16%506.2K$9.5M
+19.99%(+84.35K)
2025-Q2: 149.7K shares2025-Q3: 240.5K shares2025-Q4: 545.1K shares2026-Q1: 421.9K shares2026-Q2: 506.2K shares
$6.83(+191.68%)
2026-06-30
ALKS
ALKERMES PLC
2.14%179.3K$9.4M
+144.92%(+106.07K)
2025-Q2: 52.9K shares2025-Q3: 44.1K shares2025-Q4: 26.4K shares2026-Q1: 73.2K shares2026-Q2: 179.3K shares
$36.95(+33.82%)
2026-06-30
PCVX
VAXCYTE INC
1.98%149.7K$8.7M
+20.13%(+25.09K)
2025-Q2: 33.5K shares2025-Q3: 86.8K shares2025-Q4: 114.0K shares2026-Q1: 124.6K shares2026-Q2: 149.7K shares
$48.01(+24.71%)
2026-06-30
TNGX
TANGO THERAPEUTICS INC
1.85%260.1K$8.1M
+149.60%(+155.88K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 104.2K shares2026-Q2: 260.1K shares
$21.09(+21.62%)
2026-06-30

About Highvista Strategies LLCโ€™s portfolio

Highvista Strategies LLC reports $438.60M in US-listed equity holdings across 147 positions in its most recent 13F filing. Its largest disclosed positions are DBC (6.4%), ABVX (3.4%) and RVMD (2.9%). The top 20 holdings account for 43.88% of reported assets. Its disclosed equity book has returned +137.16% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.

Portfolio concentration

Portfolio concentration
DBC โ€” 9.0% ($28.19M)ABVX โ€” 4.8% ($15.06M)RVMD โ€” 4.0% ($12.54M)DFTX โ€” 3.7% ($11.43M)IMVT โ€” 3.4% ($10.71M)PRAX โ€” 3.2% ($10.11M)RLAY โ€” 3.0% ($9.47M)ALKS โ€” 3.0% ($9.39M)PCVX โ€” 2.8% ($8.70M)TNGX โ€” 2.6% ($8.13M)Other โ€” 60.3% ($188.23M)
40%in top 10
  • DBC9.0%
  • ABVX4.8%
  • RVMD4.0%
  • DFTX3.7%
  • IMVT3.4%
  • PRAX3.2%
  • RLAY3.0%
  • ALKS3.0%
  • PCVX2.8%
  • TNGX2.6%
  • Other60.3%

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

New buys
2
CCCCC4 THERAPEUTICS INC1.4%
RLMDRELMADA THERAPEUTICS INC0.7%
Added to
27
ALKSALKERMES PLC+144.9%
TNGXTANGO THERAPEUTICS INC+149.6%
ELVNENLIVEN THERAPEUTICS INC+88.6%
TVTXTRAVERE THERAPEUTICS INC+137.4%
+23 more
Trimmed
20
SYRESPYRE THERAPEUTICS INC-46.8%
ORKAORUKA THERAPEUTICS INC-46.9%
AMZNAMAZON COM INC-40.2%
GHRSGH RESEARCH PLC-25.5%
+16 more

Unlock alerts, watchlists & AI chat

Sign up free to track Highvista Strategies LLC, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Highvista Strategies LLCโ€™s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1335325). View Highvista Strategies LLCโ€™s 13F filings on SEC

More 13F analyses

View all